Setrobuvir

Drug Profile

Setrobuvir

Alternative Names: AN598; ANA-598; RG 7790; RO 5466731

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Anadys Pharmaceuticals
  • Developer Anadys Pharmaceuticals; Roche
  • Class Antivirals; Benzothiadiazines; Small molecules
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Hepatitis C
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 22 Apr 2015 Discontinued - Phase-I for Hepatitis C (Combination therapy) in Hungary (PO, capsule)
  • 22 Apr 2015 Discontinued - Phase-I for Hepatitis C (In volunteers) in Netherlands (PO, tablet & capsule)
  • 22 Apr 2015 Discontinued - Phase-II for Hepatitis C (Combination therapy) in USA, Australia, Canada, Germany, New Zealand, Poland and Puerto Rico (PO, capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top